[Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].
Ibarrola
M
M
Baraia-Etxaburu
J
J
Sánchez
R
R
Teira
R
R
Unzaga
J
J
Miguel Santamaría
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology*; D000328:Adult; D010131:Aminosalicylic Acid / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004917:Erythromycin / Q000494:pharmacology; D004977:Ethambutol / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology* / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology*; D019909:Mycobacterium kansasii / Q000187:drug effects / Q000302:isolation & purification*; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D013307:Streptomycin / Q000494:pharmacology; D016312:Treatment Refusal
D010131:Aminosalicylic Acid; D004917:Erythromycin; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin